Tracers / [68Ga]BL34
[68Ga]BL34
Also written as [Ga-68]Ga-BL34
- Radionuclide
- Ga-68 t½ 67.71 min
- Modality
- Therapy
- Production route
- —
- Stage
- preclinical study
- Syntheses indexed
- 1
What it is
- Compound class
- CXCR4-targeting cyclic peptide with DOTA chelator
- Target / mechanism
- CXCR4 (C-X-C chemokine receptor 4) antagonist/binder PMID 41611474
- Clinical application
- Preclinical theranostic imaging and therapy of CXCR4-expressing mantle cell lymphoma model PMID 41611474
- Theranostic pair
- <a href="/tracers/lu177-bl34/">lu177-bl34</a>
Regulatory status
- FDA
- —
- EMA (centralised)
- —
- Other approvals
- —
- Brand names
- —
Clinical use
- Typical injected activity
- —
- Uptake time
- —
Reported in the literature. Not a dosing recommendation.
Published syntheses
| Module | Cassette | Purification | Yield % | RCP % | Precursor / supplier | Source |
|---|---|---|---|---|---|---|
| — | — | — | 73.5 ± 1.9% | >99% | BL34 (10) | 41611474 2026 J Nucl Med |
Need this precursor?We can point you to suppliers for [68Ga]BL34, or handle the enquiry for you.
Get in touchNotes
Added at stage 22: promoted from 'Reported once' (single-article, no diagnostic pair at discovery) because a full-text synthesis with extracted data exists in parsed-therapy.xlsx -- PMID(s): 41611474. Target/mechanism, clinical application, indications, approval and precursor fields still need per-agent research and are intentionally left empty. Stage set/updated at stage 23 from PMID 41611474: '[68Ga]Ga-BL34 and [177Lu]Lu-BL34 showed excellent imaging and therapeutic properties in preclinical studies and are promising candidates for clinical translation.'.